Abstract:Non-alcoholic fatty liver disease (NAFLD) is a growing burden on European healthcare [<a href="#CR1">1</a>], with estimated annual healthcare costs of €19 billion EUR within the EU-5 region (France, Germany, Italy, Spain and the United Kingdom) [<a href="#CR2">2</a>]. In studies with long-term follow-up, excess mortality in people with NAFLD was shown to be dependent on the degree of underlying hepatic fibrosis [<a href="#CR3">3</a>]. Importantly, NAFLD also significantly impairs patients' quality of life [<a href="#CR4">4</a>]. The histological definition of both the presence of the inflammatory subtype of the disease, which is commonly called non-alcoholic steatohepatitis (NASH), and hepatic fibrosis, causes challenges for all epidemiological studies on the prevalence of the disease in Europe.In a recent article published in , Alexander et al. [<a href="#CR5">5</a>] undertook an enormous effort to extract data from the European Medical Information Framework in the UK, Netherlands, Italy, and Spain. They analyzed data from the electronic medical records of more than 18 million European patients with codes for NAFLD and (in some countries) for NASH. The control cohort constituted matched cases with up to 100 non-NAFLD patients for each NAFLD/NASH case and took into account GP practice site, age, sex and healthcare utilization habits into account. This represents one of the most comprehensive and largest control populations; for instance, The Health Information Network covers up to 6.2% of the patients cared for in UK-based GP practices.The authors confirm established risk factors that are relevant for NALFD; namely type 2 diabetes, arterial hypertension and obesity [<a href="#CR6">6</a>]. Importantly, the study underlines the relevance of these risk factors in a non-referral based, non-high risk population and expands available knowledge through this very large real-world dataset. The authors observed a hazard ratio for cirrhosis of 4.73 (95% CI: 2.43–9.19) and 3.51 for hepatocellular carcinoma (95% CI: 1.72–7.16), underlining the relevance of liver-related outcomes in patients with NAFLD. The incidences of these diagnoses were even higher when the surrogate score for the presence of advanced fibrosis (in this case Fibrosis-4 score [Fib-4]) was ranked as high-risk. While it is likely that a number of NAFLD/NASH cases were not coded in the available healthcare records, this large real-world study cohort highlights the contribution of diabetes as a strong and independent predictor of advanced liver disease and hepatocellular carcinoma, which is in line with previous data and recent data from the USA [<a href="#CR7">7</a>]. Interestingly, the median time between coding liver disease and cirrhosis was, in general, short, ranging between 0.5 and 2.9 years. This highlights shortcomings in the current practice aiming to identify patients with developing liver disease at an early stage.Considering all available data, including the confirmation arising from this study, the reality of liver disease in metabolically diseased patients is highlighted: diagnosis is made at a late stage. It can take a long time – even several years – to develop advanced liver disease, during which time preventative or even therapeutic approaches could be implemented. However, the fact that many patients are diagnosed at an advanced stage, means that they are prevented from modifying the risk factors responsible for driving the progression of liver disease. This must be highlighted, particularly to primary and secondary care providers. To achieve this, the scientific field urgently needs real-world data from unselected clinical cohorts that represent the disease spectrum of the general population. In the current study, 0.7% of included patients had a diagnosis of NAFLD/NASH; this should be interpreted in light of the 24% estimated global prevalence of NAFLD [<a href="#CR8">8</a>]. Therefore, this study evaluates not the tip of the iceberg, but the tip of the tip of the iceberg.Although this cohort probably represents a selected subtype of NAFLD/NASH, this study gives us a real world insight into the low awareness of NAFLD/NASH in primary care. We also learn that having a code for NAFLD/NASH does not, in itself, significantly raise awareness of this disease. With the advent of medical therapies for the treatment of NAFLD [<a href="#CR9">9</a>], the minimalistic approach to this patient population will be likely to change. It should also be highlighted that, even in the absence of a liver-directed, specific therapy, NAFLD is an 'indicator disease', which identifies patients at risk of developing d-Abstract Truncated-

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort

Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany

High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death

Severity of Nonalcoholic Fatty Liver Disease and Risk of Future Ischemic Stroke Events.

Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals

Risk of Adverse Events in Anticoagulated Patients With Atrial Fibrillation and Nonalcoholic Fatty Liver Disease

Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies

Nonalcoholic Fatty Liver Disease as a Potential Risk Factor for Cardiovascular Disease in Patients with Type 2 Diabetes: A Prospective Cohort Study

Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers

Abstract 18146: Increased Physical Activity is Associated With Lower Risk of Non Alcoholic Fatty Liver Disease Across Spectrum of Cardiometabolic Risk

Non-alcoholic fatty liver disease increases the risk of cardiovascular disease in young adults and children: a systematic review and meta-analysis of cohort studies

Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis

Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study

Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis